S&P Futures
4,365.00 +4.00 (+0.09%) Dow Futures
34,262.00 +30.00 (+0.09%) Nasdaq Futures
14,887.50 +18.00 (+0.12%) Russell 2000 Futures
1,796.20 +3.50 (+0.20%) Crude Oil
90.38 +0.35 (+0.39%) Gold
1,944.40 -1.20 (-0.06%)
Century Therapeutics, Inc. (IPSC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1700 |
| Open | 2.1600 |
| Bid | 2.1000 x 1200 |
| Ask | 2.3200 x 800 |
| Day's Range | 2.1000 - 2.2400 |
| 52 Week Range | 2.1000 - 11.9500 |
| Volume | |
| Avg. Volume | 88,770 |
| Market Cap | 129.691M |
| Beta (5Y Monthly) | 0.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for IPSC
Related Research
- Century Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/24/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
ZacksCentury Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -3.70% and 93.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireCentury Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended second quarter 2023 with cash, cash equivalents, and investments of $301.0 million; Cash runway expected into 2026 – PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-d
Simply Wall St.Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago
It's not a secret that every investor will make bad investments, from time to time. But serious investors should think...
